Results 271 to 280 of about 97,767 (354)

Enhertu as an effective treatment for metastatic lung cancer with brain metastasis recurrence: a case report. [PDF]

Ann Med Surg (Lond)
Mohammad Akram W, Kannan S, Tirmazy SH, Hamza D.   +3 more
europepmc   +1 more source

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.

JAMA Netw Open
Jänne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, Ninomiya K, Kubo T, Pérol M, Felip E, Hayashi H, Nakagawa K, Shimizu J, Nagasaka M, Pereira K, Taguchi A, Ali A, Karnoub M, Yonemochi R, Leung D, Li BT.   +20 more
europepmc   +1 more source

Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer. [PDF]

Breast Cancer Res Treat
Yamaguchi Y, Hoshino M, Shimoi T, Tamura H, Natori Y, Saiki T, Yamanaka T, Kitadai R, Saito A, Kita S, Maejima A, Kojima Y, Sudo K, Maeshima AM, Murata T, Takayama S, Naoi Y, Yonemori K, Yoshida M.   +18 more
europepmc   +1 more source

Prognostic scoring based on ER, PgR and HER2-low from the CYCLHER study: strengths and unaddressed challenges for global clinical application. [PDF]

Breast
Tan Y, Cheng B, Feng Z, He K, Xie X.
europepmc   +1 more source

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia. [PDF]

Asia Pac J Clin Oncol
Redfern A, Lim E, Lakhani S, Pathmanathan N, Selva-Nayagam S, McCarthy N, Yeo B, Dessauvagie B, Farshid G.   +8 more
europepmc   +1 more source

Destiny

, 1992
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Lancet, The, 2023
BACKGROUND In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population with scarce ...
Joaquin Gavilá Gregori, Manuel Ruiz Borrego   +1 more
exaly   +2 more sources